J Bone Miner Res 24:1672–1680PubMedCrossRef 24. Borggrefe J, Graeff C, Nickelsen TN, Marin F, Glüer CC (2010) Quantitative computed tomography assessment of the effects of 24 months of teriparatide treatment on 3-D femoral neck bone distribution, geometry and bone strength: results from the PLX3397 in vivo EUROFORS study. J Bone Miner Res 25:472–481. doi:10.​1359/​JBMR.​090820

PubMedCrossRef 25. Genant HK, Grampp S, Glüer CC, Faulkner KG, Jergas M, Hagiwara S, van Kuijk C (1994) Universal standardisation for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 9:1503–1514PubMedCrossRef 26. Hanson J (1997) Standardization of femur bone mineral density. J Bone Miner Res 12:1316–1317PubMedCrossRef

PF-6463922 chemical structure 27. Graeff C, Timm W, Nickelsen TN, Farrerons J, Marin F, Barker C, Glüer C-C, for the EUROFORS High Resolution Quantitative Computed Tomography Substudy Group (2007) Monitoring teriparatide associated changes in vertebral microstructure by high-resolution computed tomography in vivo: results from the EUROFORS study. J Bone Miner Res 22:1426–1433PubMedCrossRef 28. Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV, EUROFORS Investigators (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide https://www.selleckchem.com/products/wortmannin.html treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852–860PubMedCrossRef 29. Bauer DC, Garnero P, Bilezikian JP, Greenspon SL, Ensrud KE, Rosen CJ, Palermo L, Black DM, for the PTH and Alendronate (PaTH) Research Group (2006) Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91:1370–1375PubMedCrossRef 30. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ, for the

PaTH Study Investigators (2005) One year of alendronate after one year else of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555–565PubMedCrossRef 31. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, for the Treatment of Osteoporosis with Parathyroid Hormone Study Group (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 146:326–339PubMed 32. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD (2000) Short-term increases in bone turnover markers predict parathyroid hormone-induce spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11:434–442PubMedCrossRef 33.